Glaxo Sued For Antitrust In 340B Program
Thursday November 1st, 2012Ed Silverman
Just seven months after Republican members of Congress began a probe into the 340B Drug Pricing Program, a Nevada healthcare clinic has filed an antitrust lawsuit accusing GlaxoSmithKline, a Nevada public health agency and a non-profit vendor that negotiates prices for medicines of abusing the program.
The lawsuit, which was filed by The Vaccine Center in Las Vegas, contends the Southern Nevada Health District buys hepatitis A and B vaccines from Glaxo and Apexus at “discriminatory” and “sharply reduced prices” in violation of the 340B program.
Consequently, the agency has been able to “crush private-sector competition, drive private medical practices and clinics out of business, and monopolize markets for fee-based immunization services,” according to the lawsuit, which was filed in federal court.
Link to Story
For more information:
Sharon Anglin Treat, Executive Director
Learn more about 340(B)